Hdl Handle:
http://hdl.handle.net/10147/208909
Title:
Tetomilast.
Authors:
O'Mahony, Seamus
Affiliation:
Cork University Hospital, Wilton, Cork, Ireland. omahonys3@shb.ie
Citation:
IDrugs. 2005 Jun;8(6):502-7.
Journal:
IDrugs : the investigational drugs journal
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208909
PubMed ID:
15906198
Abstract:
Otsuka is developing a once-daily oral formulation of the phosphodiesterase-4 inhibitor tetomilast for the potential treatment of ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II).
Language:
eng
MeSH:
3',5'-Cyclic-AMP Phosphodiesterases/*drug effects; Animals; Anti-Inflammatory Agents, Non-Steroidal/adverse effects/chemical; synthesis/contraindications/pharmacology/*therapeutic use; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colitis, Ulcerative/drug therapy; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Phosphodiesterase Inhibitors/adverse effects/chemical; synthesis/contraindications/pharmacology/*therapeutic use; Pulmonary Disease, Chronic Obstructive/drug therapy; Structure-Activity Relationship; Thiazoles/adverse effects/chemical; synthesis/contraindications/pharmacology/*therapeutic use
ISSN:
1369-7056 (Print); 1369-7056 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Mahony, Seamusen_GB
dc.date.accessioned2012-02-03T15:07:08Z-
dc.date.available2012-02-03T15:07:08Z-
dc.date.issued2012-02-03T15:07:08Z-
dc.identifier.citationIDrugs. 2005 Jun;8(6):502-7.en_GB
dc.identifier.issn1369-7056 (Print)en_GB
dc.identifier.issn1369-7056 (Linking)en_GB
dc.identifier.pmid15906198en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208909-
dc.description.abstractOtsuka is developing a once-daily oral formulation of the phosphodiesterase-4 inhibitor tetomilast for the potential treatment of ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II).en_GB
dc.language.isoengen_GB
dc.subject.mesh3',5'-Cyclic-AMP Phosphodiesterases/*drug effectsen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal/adverse effects/chemicalen_GB
dc.subject.meshsynthesis/contraindications/pharmacology/*therapeutic useen_GB
dc.subject.meshClinical Trials as Topicen_GB
dc.subject.meshClinical Trials, Phase II as Topicen_GB
dc.subject.meshClinical Trials, Phase III as Topicen_GB
dc.subject.meshColitis, Ulcerative/drug therapyen_GB
dc.subject.meshCyclic Nucleotide Phosphodiesterases, Type 4en_GB
dc.subject.meshHumansen_GB
dc.subject.meshPhosphodiesterase Inhibitors/adverse effects/chemicalen_GB
dc.subject.meshsynthesis/contraindications/pharmacology/*therapeutic useen_GB
dc.subject.meshPulmonary Disease, Chronic Obstructive/drug therapyen_GB
dc.subject.meshStructure-Activity Relationshipen_GB
dc.subject.meshThiazoles/adverse effects/chemicalen_GB
dc.subject.meshsynthesis/contraindications/pharmacology/*therapeutic useen_GB
dc.titleTetomilast.en_GB
dc.contributor.departmentCork University Hospital, Wilton, Cork, Ireland. omahonys3@shb.ieen_GB
dc.identifier.journalIDrugs : the investigational drugs journalen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.